Role of matrix metalloproteinases in animal models of ischemic stroke

Current Vascular Pharmacology

Volumn 13, Issue 2, 2015, Pages 161-166

  Lenglet, Sébastien ^a   Montecucco, Fabrizio ^a,b   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Inflammation; Matrix metalloproteinase; Stroke

Indexed keywords

CLAUDIN 5; COLLAGENASE 3; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; OCCLUDIN; PROTEIN ZO1; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1; STROMELYSIN; STROMELYSIN 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CELL DEATH; CELL MIGRATION; INFLAMMATION; INFLAMMATORY INFILTRATE; MIDDLE CEREBRAL ARTERY OCCLUSION; MYELINATION; NEOVASCULARIZATION (PATHOLOGY); NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NONHUMAN; REGULATORY MECHANISM; SUBVENTRICULAR ZONE; ANIMAL; BRAIN ARTERY; BRAIN CIRCULATION; CAPILLARY PERMEABILITY; DISEASE MODEL; ENZYMOLOGY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; STROKE; VASCULAR REMODELING;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CAPILLARY PERMEABILITY; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; HUMANS; MATRIX METALLOPROTEINASES; SIGNAL TRANSDUCTION; STROKE; VASCULAR REMODELING;

EID: 84929722842     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660161     Document Type: Article

References (83)

1. Markus HS. Stroke genetics. Hum Mol Genet 2011; 20(R2): R124-31
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57
3. Jones F, Riazi A. Self-efficacy and self-management after stroke: a systematic review. Disabil Rehabil 2011; 33: 797-810
4. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53
5. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003; 362: 1211-24
6. Rosamond W, Flegal K, Furie K, et al.Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146
7. Farooqui AA, Horrocks LA. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006; 12: 245-60
8. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003; 62: 127-36
9. Montecucco F, Lenglet S, Gayet-Ageron A, et al.Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 2010; 41: 1394-404
10. Al-Shahi R, White PM, Davenport RJ, Lindsay KW. Subarachnoid haemorrhage. BMJ 2006; 333: 235-40
11. Al-Shahi Salman R, Labovitz DL, Stapf C. Spontaneous intracerebral haemorrhage. BMJ 2009; 339: b2586
12. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271-80
13. Sudlow C. Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. Pract Neurol 2008; 8: 141-57
14. Montecucco F, Quercioli A, Mirabelli-Badenier M, Viviani GL, Mach F. Statins in the treatment of acute ischemic stroke. Curr Pharm Biotechnol 2012; 13: 68-76
15. Bailey EL, McCulloch J, Sudlow C, Wardlaw JM. Potential animal models of lacunar stroke: a systematic review. Stroke 2009; 40: e451-8
16. Wiebers DO, Adams HP, Jr., Whisnant JP. Animal models of stroke: are they relevant to human disease? Stroke 1990; 21: 1-3
17. Krafft PR, Bailey EL, Lekic T, et al.Etiology of stroke and choice of models. Int J Stroke 2012; 7: 398-406
18. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73
19. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34
20. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8
21. Gasche Y, Soccal PM, Kanemitsu M, Copin JC. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 2006; 11: 1289-301
22. Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2: ii43-7
23. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238: 53-6
24. Gidday JM, Gasche YG, Copin JC, et al.Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289: H558-68
25. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-33
26. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23: 406-15
27. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al.Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-406
28. Sole S, Petegnief V, Gorina R, Chamorro A, Planas AM. Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol 2004; 63: 338-49
29. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin- 1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 5: 1732-9
30. Lee SR, Wang X, Tsuji K, Lo EH. Extracellular proteolytic pathophysiology in the neurovascular unit after stroke. Neurol Res 2004; 26: 854-61
31. Gasche Y, Fujimura M, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19: 1020-8
32. Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001; 8: 834-46
33. Tejima E, Zhao BQ, Tsuji K, et al.Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab 2007; 27: 460-8
34. Hu Q, Chen C, Khatibi NH, et al.Lentivirus-mediated transfer of MMP-9 shRNA provides neuroprotection following focal ischemic brain injury in rats. Brain Res 2011;1367: 347-59
35. Hamann GF, Burggraf D, Martens HK, et al.Mild to moderate hypothermia prevents microvascular basal lamina antigen loss in experimental focal cerebral ischemia. Stroke 2004; 35:764-9
36. Hamann GF, Liebetrau M, Martens H, et al.Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 2002; 22: 526-33
37. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998; 141: 1539-50
38. Morita K, Itoh M, Saitou M, et al.Subcellular distribution of tight junction-associated proteins (occludin, ZO-1, ZO-2) in rodent skin. J Invest Dermatol 1998; 110: 862-6
39. Asahi M, Wang X, Mori T, et al.Effects of matrix metalloproteinase- 9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-32
40. Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000; 123: 698-709
41. Yang Y, Rosenberg GA. MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol 2011; 762: 333-45
42. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL, Jr., del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004; 35: 998-1004
43. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1- MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996; 393: 101-4
44. Mazzieri R, Masiero L, Zanetta L, et al.Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. Embo J 1997; 16: 2319-32
45. Chang DI, Hosomi N, Lucero J, et al.Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 1408-19
46. Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci 2012; 32: 3044-57
47. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709
48. Kelly-Hayes M. Influence of age and health behaviors on stroke risk: lessons from longitudinal studies. J Am Geriatr Soc 2010; 58 Suppl 2: S325-8
49. Mirabelli-Badenier M, Braunersreuther V, Lenglet S, et al.Pathophysiological role of inflammatory molecules in paediatric ischaemic brain injury. Eur J Clin Invest 2012; 42: 784-94
50. Petcu EB, Sfredel V, Platt D, Herndon JG, Kessler C, Popa-Wagner A. Cellular and molecular events underlying the dysregulated response of the aged brain to stroke: a mini-review. Gerontology 2008; 54: 6-17
51. Brown AW, Marlowe KJ, Bjelke B. Age effect on motor recovery in a post-acute animal stroke model. Neurobiol Aging 2003; 24: 607-14
52. Markus TM, Tsai SY, Bollnow MR, Farrer RG, O'Brien TE, Kindler- Baumann DR, et al. Recovery and brain reorganization after stroke in adult and aged rats. Ann Neurol 2005; 58: 950-3
53. Popa-Wagner A, Schroder E, Walker LC, Kessler C. beta-Amyloid precursor protein and ss-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: effect of age. Stroke 1998; 29: 2196-202
54. Liguz-Lecznar M, Ziemka-Nalecz M, Aleksy M, Kossut M, Skangiel-Kramska J, Nowicka D. Comparison of matrix metalloproteinase activation after focal cortical ischemia in young adult and aged mice. J Neurosci Res 2012; 90: 203-12
55. Benuck M, Banay-Schwartz M, DeGuzman T, Lajtha A. Changes in brain protease activity in aging. J Neurochem 1996; 67: 2019-29
56. Bernath E, Kupina N, Liu MC, Hayes RL, Meegan C, Wang KK. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging 2006; 27: 624-32
57. Rosenberg GA, Cunningham LA, Wallace J, et al.Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 2001; 893: 104-12
58. Burgess RW, Dickman DK, Nunez L, Glass DJ, Sanes JR. Mapping sites responsible for interactions of agrin with neurons. J Neurochem 2002; 83: 271-84
59. Hilgenberg LG, Ho KD, Lee D, O'Dowd DK, Smith MA. Agrin regulates neuronal responses to excitatory neurotransmitters in vitro and in vivo. Mol Cell Neurosci 2002; 19: 97-110
60. Witte OW, Bidmon HJ, Schiene K, Redecker C, Hagemann G. Functional differentiation of multiple perilesional zones after focal cerebral ischemia. J Cereb Blood Flow Metab 2000; 20: 1149-65
61. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 2006; 23: 87-96
62. Jalal FY, Yang Y, Thompson J, Lopez AC, Rosenberg GA. Myelin loss associated with neuroinflammation in hypertensive rats. Stroke 2012; 43: 1115-22
63. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002; 13 Suppl 2: 7-10
64. Orbe J, Barrenetxe J, Rodriguez JA, et al.Matrix metalloproteinase- 10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation 2011; 124: 2909-19
65. Wells JE, Biernaskie J, Szymanska A, Larsen PH, Yong VW, Corbett D. Matrix metalloproteinase (MMP)-12 expression has a negative impact on sensorimotor function following intracerebral haemorrhage in mice. Eur J Neurosci 2005; 21: 187-96
66. Nagel S, Sandy JD, Meyding-Lamade U, Schwark C, Bartsch JW, Wagner S. Focal cerebral ischemia induces changes in both MMP-13 and aggrecan around individual neurons. Brain Res 2005; 1056: 43-50
67. Rosell A, Alvarez-Sabin J, Arenillas JF, et al.A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005; 36: 1415-20
68. Cuadrado E, Rosell A, Borrell-Pages M, et al.Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J Cereb Blood Flow Metab 2009; 29: 398-410
69. Leeman MF, Curran S, Murray GI. The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002; 37: 149-66
70. Kaczmarek L, Lapinska-Dzwonek J, Szymczak S. Matrix metalloproteinases in the adult brain physiology: a link between c- Fos, AP-1 and remodeling of neuronal connections? Embo J 2002; 21: 6643-8
71. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002; 8: 963-70
72. Lin TN, Sun SW, Cheung WM, Li F, Chang C. Dynamic changes in cerebral blood flow and angiogenesis after transient focal cerebral ischemia in rats. Evaluation with serial magnetic resonance imaging. Stroke 2002; 33: 2985-91
73. Tsai PT, Ohab JJ, Kertesz N, et al.A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-74
74. Vaillant C, Meissirel C, Mutin M, Belin MF, Lund LR, Thomasset N. MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Mol Cell Neurosci 2003; 24: 395-408
75. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-44
76. Lee SR, Kim HY, Rogowska J, et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 2006; 26: 3491-5
77. Barkho BZ, Munoz AE, Li X, Li L, Cunningham LA, Zhao X. Endogenous matrix metalloproteinase (MMP)-3 and MMP-9 promote the differentiation and migration of adult neural progenitor cells in response to chemokines. Stem Cells 2008; 26: 3139-49
78. da Silva PG, Benton JL, Beltz BS, Allodi S. Adult neurogenesis: ultrastructure of a neurogenic niche and neurovascular relationships. PLoS One 2012; 7: e39267
79. Taguchi A, Soma T, Tanaka H, et al.Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004; 114: 330-8
80. Wang L, Zhang ZG, Zhang RL, et al.Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 2006; 26: 5996-6003
81. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-7
82. Pham LD, Hayakawa K, Seo JH, et al.Crosstalk between oligodendrocytes and cerebral endothelium contributes to vascular remodeling after white matter injury. Glia 2012; 60: 875-81
83. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003; 23: 11127-35.